Filter posts

Perspectives on today's IPO candidates

Some speculation is coming back into the sector but most movement in public markets is …

Positive results for Logical Therapeutics’ LT-NS001 vs. Naproxen clinical study

Logical Therapeutics, Inc. announced positive results of a Phase I/II clinical trial evaluating the gastrointestinal …

Trubion reports positive data from Phase 2B TRU-015 study

Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced favorable safety and efficacy data following administration of a …

Rexahn reports Phase IIa data for Serdaxin

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN) announced top-line results from a Phase IIa clinical study …

Inovio begins HIV clinical trial of DNA vaccine

Inovio Biomedical Corporation (NYSE Amex: INO) and the HIV Vaccine Trials Network (HVTN) initiated a …

Provectus starts compassionate use program for PV-10

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) expanded its compassionate use program for PV-10, making the agent, …

Novavax gets NIH grant

Novavax, Inc. (NASDAQ:NVAX) has received a Small Business and Innovation Research grant from the National …

Canadian patent strengthens IP for Allon’s 2nd technology platform

Allon Therapeutics Inc. (TSX: NPC), announced today that the intellectual property underlying its activity-dependent neurotrophic …

Positive Phase 2 results for TOPICA’s luliconazole

TOPICA Pharmaceuticals had positive results from its Phase 2 clinical study evaluating luliconazole, a topical …

WILEX receives approval for Phase I trial

WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) announced that the German …